{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:05:46Z","timestamp":1791615946722,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012644","name":"Friends of FSH Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012644","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Facioscapulohumeral dystrophy (FSHD) is a major muscular dystrophy characterized by asymmetric fatty replacement of muscles. We aimed to determine the initiation site and progression profile of the disease in lower extremity muscles of FSHD patients by assessing fat infiltration along their full proximo-distal axis using quantitative MRI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Nine patients underwent MRI of lower extremities to assess end-to-end muscle fat fractions (FFs) and inflammatory lesions. Seven patients underwent the same MRI ~3.5 years later. Individual muscles (n\u2009=\u2009396) were semi-automatically segmented to calculate average FFs over all slices covering whole muscles. To assess disease progression we determined FF changes in 5 adjacent muscle segments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We provide evidence that fat replacement commonly starts at the distal end of affected muscles where the highest FFs occur (p\u2009&lt;\u20090.001). It progresses in a wave-like manner in the proximal direction at an increasing rate with the highest value (4.9\u2009\u00b1\u20092.7%\/year) for muscles with baseline FFs of 30\u201340%. Thereafter it proceeds at a slower pace towards the proximal muscle end. In early phases of disease, inflammatory lesions preferentially occur at the distal muscle end. Compared with whole-muscle analysis, the common FF assessments using only few MR slices centrally placed in muscles are significantly biased (~50% in progression rate).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings identify the distal end of leg muscles as a prime location for disease initiation in FSHD and demonstrate a wave-like progression towards the proximal end, consistent with proposed disease mechanisms. End-to-end whole-muscle fat assessment is essential to properly diagnose FSHD and its progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s43856-022-00217-1","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T05:00:51Z","timestamp":1669870851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Whole-muscle fat analysis identifies distal muscle end as disease initiation site in facioscapulohumeral muscular dystrophy"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-9336","authenticated-orcid":false,"given":"Linda","family":"Heskamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Ogier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bendahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-4562","authenticated-orcid":false,"given":"Arend","family":"Heerschap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"217_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-4-12","volume":"4","author":"R Tawil","year":"2014","unstructured":"Tawil, R., van der Maarel, S. M. & Tapscott, S. J. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet. Muscle 4, 12 (2014).","journal-title":"Skelet. Muscle"},{"key":"217_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/practneurol-2015-001353","volume":"16","author":"K Mul","year":"2016","unstructured":"Mul, K. et al. What\u2019s in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract. Neurol. 16, 201\u2013207 (2016).","journal-title":"Pract. Neurol."},{"key":"217_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.molmed.2011.01.001","volume":"17","author":"SM Van der Maarel","year":"2011","unstructured":"Van der Maarel, S. M., Tawil, R. & Tapscott, S. J. Facioscapulohumeral muscular dystrophy and DUX4: Breaking the silence. Trends Mol. Med. 17, 252\u2013258 (2011).","journal-title":"Trends Mol. Med."},{"key":"217_CR4","doi-asserted-by":"crossref","unstructured":"Lim, K. R. Q., Nguyen, Q. & Yokota, T. DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy. Int. J. Mol. Sci. 21, 729 (2020).","DOI":"10.3390\/ijms21030729"},{"key":"217_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01760-1","volume":"16","author":"T Sch\u00e4tzl","year":"2021","unstructured":"Sch\u00e4tzl, T., Kaiser, L. & Deigner, H.-P. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update. Orphanet J. Rare Dis. 16, 129 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"217_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JND-200554","volume":"8","author":"LH Wang","year":"2021","unstructured":"Wang, L. H. & Tawil, R. Current therapeutic approaches in FSHD. J. Neuromuscul. Dis. 8, 441\u2013451 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"217_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","volume":"17","author":"A Tassin","year":"2013","unstructured":"Tassin, A. et al. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? J. Cell. Mol. Med. 17, 76\u201389 (2013).","journal-title":"J. Cell. Mol. Med."},{"key":"217_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00415-006-0230-z","volume":"253","author":"DB Olsen","year":"2006","unstructured":"Olsen, D. B., Gideon, P., Jeppesen, T. D. & Vissing, J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. J. Neurol. 253, 1437\u20131441 (2006).","journal-title":"J. Neurol."},{"key":"217_CR9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.clinbiomech.2007.07.013","volume":"22","author":"M Iosa","year":"2007","unstructured":"Iosa, M. et al. Mobility assessment of patients with facioscapulohumeral dystrophy. Clin. Biomech. 22, 1074\u20131082 (2007).","journal-title":"Clin. Biomech."},{"key":"217_CR10","doi-asserted-by":"publisher","first-page":"e85416","DOI":"10.1371\/journal.pone.0085416","volume":"9","author":"BH Janssen","year":"2014","unstructured":"Janssen, B. H. et al. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS ONE 9, e85416 (2014).","journal-title":"PLoS ONE"},{"key":"217_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.nmd.2017.11.017","volume":"28","author":"MA Marra","year":"2018","unstructured":"Marra, M. A. et al. Specific muscle strength is reduced in facioscapulohumeral dystrophy: an MRI based musculoskeletal analysis. Neuromuscul. Disord. 28, 238\u2013245 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"217_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-160145","volume":"3","author":"PG Carlier","year":"2016","unstructured":"Carlier, P. G. et al. Skeletal muscle quantitative nuclear magnetic resonance imaging and spectroscopy as an outcome measure for clinical trials. J. Neuromuscul. Dis. 3, 1\u201328 (2016).","journal-title":"J. Neuromuscul. Dis."},{"key":"217_CR13","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1212\/WNL.0000000000004647","volume":"89","author":"K Mul","year":"2017","unstructured":"Mul, K. et al. Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology 89, 2057\u20132065 (2017).","journal-title":"Neurology"},{"key":"217_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-016-8361-3","volume":"264","author":"G Andersen","year":"2017","unstructured":"Andersen, G. et al. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J. Neurol. 264, 438\u2013447 (2017).","journal-title":"J. Neurol."},{"key":"217_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04134-7","volume":"22","author":"LH Wang","year":"2021","unstructured":"Wang, L. H. et al. Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy. BMC Musculoskelet. Disord. 22, 262 (2021).","journal-title":"BMC Musculoskelet. Disord."},{"key":"217_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.nmd.2009.02.009","volume":"19","author":"HE Kan","year":"2009","unstructured":"Kan, H. E. et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 19, 357\u2013362 (2009).","journal-title":"Neuromuscul. Disord."},{"key":"217_CR17","first-page":"0","volume":"0","author":"JR Dahlqvist","year":"2019","unstructured":"Dahlqvist, J. R. et al. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. J. Neurol. 0, 0 (2019).","journal-title":"J. Neurol."},{"key":"217_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.04996","volume":"4","author":"Q Feng","year":"2015","unstructured":"Feng, Q. et al. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. Elife 4, 1\u201313 (2015).","journal-title":"Elife"},{"key":"217_CR19","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","volume":"24","author":"AM Rickard","year":"2015","unstructured":"Rickard, A. M., Petek, L. M. & Miller, D. G. Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. Hum. Mol. Genet. 24, 5901\u20135914 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"217_CR20","doi-asserted-by":"crossref","unstructured":"Ogier, A., Sdika, M., Foure, A., Le Troter, A. & Bendahan, D. Individual muscle segmentation in MR images: a 3D propagation through 2D non-linear registration approaches. In 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 317\u2013320 (IEEE, 2017).","DOI":"10.1109\/EMBC.2017.8036826"},{"key":"217_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10875-010-9474-6","volume":"31","author":"G Frisullo","year":"2011","unstructured":"Frisullo, G. et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J. Clin. Immunol. 31, 155\u201366 (2011).","journal-title":"J. Clin. Immunol."},{"key":"217_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/mrm.28030","volume":"83","author":"AC Ogier","year":"2020","unstructured":"Ogier, A. C. et al. A novel segmentation framework dedicated to the follow\u2010up of fat infiltration in individual muscles of patients with neuromuscular disorders. Magn. Reson. Med. 83, 1825\u20131836 (2020).","journal-title":"Magn. Reson. Med."},{"key":"217_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jmri.20804","volume":"25","author":"E Mercuri","year":"2007","unstructured":"Mercuri, E. et al. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J. Magn. Reson. Imaging 25, 433\u2013440 (2007).","journal-title":"J. Magn. Reson. Imaging"},{"key":"217_CR24","doi-asserted-by":"publisher","first-page":"e1211","DOI":"10.1212\/WNL.0000000000010155","volume":"95","author":"JR Dahlqvist","year":"2020","unstructured":"Dahlqvist, J. R. et al. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy. Neurology 95, e1211\u2013e1221 (2020).","journal-title":"Neurology"},{"key":"217_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nmd.2017.02.009","volume":"27","author":"MT Hooijmans","year":"2017","unstructured":"Hooijmans, M. T. et al. Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy. Neuromuscul. Disord. 27, 458\u2013464 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"217_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13072-018-0215-z","volume":"11","author":"P Haynes","year":"2018","unstructured":"Haynes, P., Bomsztyk, K. & Miller, D. G. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele. Epigenetics Chromatin 11, 47 (2018).","journal-title":"Epigenetics Chromatin"},{"key":"217_CR27","doi-asserted-by":"publisher","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","volume":"6","author":"L Snider","year":"2010","unstructured":"Snider, L. et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 6, e1001181 (2010).","journal-title":"PLoS Genet."},{"key":"217_CR28","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1113\/JP280771","volume":"599","author":"L Heskamp","year":"2021","unstructured":"Heskamp, L. et al. Post\u2010exercise intramuscular O 2 supply is tightly coupled with a higher proximal\u2010to\u2010distal ATP synthesis rate in human tibialis anterior. J. Physiol. 599, 1533\u20131550 (2021).","journal-title":"J. Physiol."},{"key":"217_CR29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1113\/JP275009","volume":"596","author":"A Boss","year":"2018","unstructured":"Boss, A. et al. Oxidative capacity varies along the length of healthy human tibialis anterior. J. Physiol. 596, 1467\u20131483 (2018).","journal-title":"J. Physiol."},{"key":"217_CR30","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/mrm.28088","volume":"83","author":"F Niess","year":"2020","unstructured":"Niess, F. et al. Interleaved 31 P MRS\/ 1 H ASL for analysis of metabolic and functional heterogeneity along human lower leg muscles at 7T. Magn. Reson. Med. 83, 1909\u20131919 (2020).","journal-title":"Magn. Reson. Med."},{"key":"217_CR31","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1152\/japplphysiol.00197.2003","volume":"95","author":"M Mizuno","year":"2003","unstructured":"Mizuno, M. et al. Regional differences in blood flow and oxygen consumption in resting muscle and their relationship during recovery from exhaustive exercise. J. Appl. Physiol. 95, 2204\u20132210 (2003).","journal-title":"J. Appl. Physiol."},{"key":"217_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2170\/jjphysiol.51.599","volume":"51","author":"H Miura","year":"2001","unstructured":"Miura, H., McCully, K., Hong, L., Nioka, S. & Chance, B. Regional difference of muscle oxygen saturation and blood volume during exercise determined by near infrared imaging device. Jpn. J. Physiol. 51, 599\u2013606 (2001).","journal-title":"Jpn. J. Physiol."},{"key":"217_CR33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/02640414.2010.489195","volume":"28","author":"AG Crenshaw","year":"2010","unstructured":"Crenshaw, A. G., Bronee, L., Krag, I. & Jensen, B. R. Oxygenation and EMG in the proximal and distal vastus lateralis during submaximal isometric knee extension. J. Sports Sci. 28, 1057\u20131064 (2010).","journal-title":"J. Sports Sci."},{"key":"217_CR34","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1093\/hmg\/ddy293","volume":"27","author":"M Sasaki-Honda","year":"2018","unstructured":"Sasaki-Honda, M. et al. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4. Hum. Mol. Genet. 27, 4024\u20134035 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"217_CR35","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.freeradbiomed.2012.06.041","volume":"53","author":"A Turki","year":"2012","unstructured":"Turki, A. et al. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. Free Radic. Biol. Med. 53, 1068\u20131079 (2012).","journal-title":"Free Radic. Biol. Med."},{"key":"217_CR36","doi-asserted-by":"publisher","first-page":"eaay0271","DOI":"10.1126\/scitranslmed.aay0271","volume":"12","author":"A Lek","year":"2020","unstructured":"Lek, A. et al. Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy. Sci. Transl. Med. 12, eaay0271 (2020).","journal-title":"Sci. Transl. Med."},{"key":"217_CR37","doi-asserted-by":"publisher","first-page":"102008","DOI":"10.1016\/j.redox.2021.102008","volume":"43","author":"A Karpukhina","year":"2021","unstructured":"Karpukhina, A. et al. Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy. Redox Biol. 43, 102008 (2021).","journal-title":"Redox Biol."},{"key":"217_CR38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00418-016-1410-2","volume":"145","author":"YB Saada","year":"2016","unstructured":"Saada, Y. B. et al. Facioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage. Histochem. Cell Biol. 145, 475\u2013483 (2016).","journal-title":"Histochem. Cell Biol."},{"key":"217_CR39","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1038\/emboj.2008.201","volume":"27","author":"D Bosnakovski","year":"2008","unstructured":"Bosnakovski, D. et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 27, 2766\u20132779 (2008).","journal-title":"EMBO J."},{"key":"217_CR40","doi-asserted-by":"publisher","first-page":"e0183825","DOI":"10.1371\/journal.pone.0183825","volume":"12","author":"F Fatehi","year":"2017","unstructured":"Fatehi, F. et al. Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: a quantitative study. PLoS ONE 12, e0183825 (2017).","journal-title":"PLoS ONE"},{"key":"217_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mus.20522","volume":"34","author":"R Tawil","year":"2006","unstructured":"Tawil, R. & Van Der Maarel, S. M. Facioscapulohumeral muscular dystrophy. Muscle Nerve 34, 1\u201315 (2006).","journal-title":"Muscle Nerve"},{"key":"217_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10545-015-9825-9","volume":"38","author":"PG Carlier","year":"2015","unstructured":"Carlier, P. G. et al. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients. J. Inherit. Metab. Dis. 38, 565\u2013572 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"key":"217_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1148\/radiol.2020192518","volume":"297","author":"L Heskamp","year":"2020","unstructured":"Heskamp, L. et al. Quantitative muscle MRI depicts increased muscle mass after a behavioral change in myotonic dystrophy type 1. Radiology 297, 132\u2013142 (2020).","journal-title":"Radiology"},{"key":"217_CR44","doi-asserted-by":"crossref","unstructured":"Otto, L. A. M. et al. Quantification of disease progression in spinal muscular atrophy with muscle MRI\u2014a pilot study. NMR Biomed. 34, e4473 (2021).","DOI":"10.1002\/nbm.4473"},{"key":"217_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1452-x","volume":"19","author":"S LoRusso","year":"2019","unstructured":"LoRusso, S. et al. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurol. 19, 224 (2019).","journal-title":"BMC Neurol."},{"key":"217_CR46","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1111\/bcp.14884","volume":"87","author":"ML Mellion","year":"2021","unstructured":"Mellion, M. L. et al. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br. J. Clin. Pharmacol. 87, 4658\u20134669 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"217_CR47","doi-asserted-by":"crossref","unstructured":"Ogier, A. C., Hostin, M.-A., Bellemare, M.-E. & Bendahan, D. Overview of MR image segmentation strategies in neuromuscular disorders. Front. Neurol. 12, 625308 (2021).","DOI":"10.3389\/fneur.2021.625308"}],"updated-by":[{"DOI":"10.1038\/s43856-023-00236-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000}}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00217-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00217-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00217-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T08:08:51Z","timestamp":1673597331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00217-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1038\/s43856-022-00217-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s43856-023-00236-6","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"13 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43856-023-00236-6","URL":"https:\/\/doi.org\/10.1038\/s43856-023-00236-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}